Saher Gill

  • Citations Per Year
Learn More
Synergy has been reported for the combination of cisplatin and cytarabine in a murine model and in several human cell lines in vitro. Clinical trials are under way with this combination. However, we were unable to demonstrate any significant synergistic interaction between these two agents in two human ovarian carcinoma cell lines with either 4-hour or(More)
Investigation of 3 families with bleeding symptoms demonstrated a defect in the collagen-binding activity of von Willebrand factor (VWF) in association with a normal VWF multimeric pattern. Genetic analysis showed affected persons to be heterozygous for mutations in the A3 domain of VWF: S1731T, W1745C, and S1783A. One person showed compound heterozygosity(More)
Patients with chemo-refractory acute myeloid leukemia (AML) have a dismal prognosis. Chimeric antigen receptor T (CART) cell therapy has produced exciting results in CD19+ malignancies and may overcome many of the limitations of conventional leukemia therapies. We developed CART cells to target CD33 (CART33) using the anti-CD33 single chain variable(More)
  • Anne F. Riddell, Keith Gomez, +7 authors Katharine Dormandy
  • 2009
Katharine Dormandy Haemophilia Centre and Thrombosis Unit, The Royal Free and University College Medical School, London NW3 2QG, United Kingdom. Department of Haematology, Imperial College Academic Health Sciences Centre, Hammersmith Hospital, London W12 0NN, United Kingdom Department of Haematology, Royal Children’s Hospital and Royal Brisbane and Women’s(More)
Two potent new ribonucleotide reductase inhibitors, 3,4,5-trihydroxybenzohydroxamic acid (VF 122) and 3,4-dihydroxybenzohydroxamic acid (VF 147), were investigated for their ability to modulate the cellular pharmacology of cytarabine (ara-C) in HL-60 cells. VF 122 and VF 147 increased the total cellular uptake of ara-C by a mean (+/- SE) of 8% +/- 3% and(More)
  • 1